pentoxifylline has been researched along with Bright Disease in 11 studies
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentoxifylline (PTX) has been shown to inhibit renal inflammation in a rat model of crescentic glomerulonephritis." | 7.75 | Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. ( Chen, YM; Lan, HY; Lan, XR; Ng, YY; Tsai, TJ; Yang, WC, 2009) |
| "Anti-Thy1 glomerulonephritis is a rat nephritis model closely simulating human mesangial proliferative glomerulonephritis." | 5.42 | Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling. ( Chen, YM; Chiang, WC; Lai, CF; Lin, SL; Wu, KD; Yang, Y, 2015) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that possesses potent anti-inflammatory and immunomudulatory effects." | 5.33 | Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2006) |
| "Crescentic glomerulonephritis is a rapidly progressive form of glomerulonephritis, but treatment remains non-specific." | 5.32 | Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. ( Chen, YM; Chiang, WC; Lan, HY; Lin, SL; Ng, YY; Tsai, TJ, 2004) |
| "Pentoxifylline (PTX) has been shown to inhibit renal inflammation in a rat model of crescentic glomerulonephritis." | 3.75 | Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. ( Chen, YM; Lan, HY; Lan, XR; Ng, YY; Tsai, TJ; Yang, WC, 2009) |
| " The present study compares the effects of the cGMP production-increasing soluble guanylate cyclase (sGC) stimulator BAY 41-2272 with those of the cGMP degradation-limiting phosphodiesterase inhibitor pentoxifylline (PTX) in a progressive model of renal fibrosis." | 3.73 | Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2006) |
| " Modification of the Th1/Th2 ratio during induction with preparations acting on the immune system cells via different mechanisms and shifting the Th1/Th2 balance towards Th2 (bisphenol A, pentoxifylline, muramyl dipeptide) increases the incidence of Th2-dependent autoimmune lupus-like glomerulonephritis." | 3.73 | Effects of preparations modifying Th1/Th2 ratio on the incidence of clinical variants of chronic graft-versus-host reaction. ( Goiman, EV; Kolesnikova, OP; Kozlov, VA; Kudaeva, OT; Lykov, AP, 2005) |
| "Anti-Thy1 glomerulonephritis is a rat nephritis model closely simulating human mesangial proliferative glomerulonephritis." | 1.42 | Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling. ( Chen, YM; Chiang, WC; Lai, CF; Lin, SL; Wu, KD; Yang, Y, 2015) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that possesses potent anti-inflammatory and immunomudulatory effects." | 1.33 | Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2006) |
| "Crescentic glomerulonephritis is a rapidly progressive form of glomerulonephritis, but treatment remains non-specific." | 1.32 | Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. ( Chen, YM; Chiang, WC; Lan, HY; Lin, SL; Ng, YY; Tsai, TJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YM | 4 |
| Chiang, WC | 3 |
| Yang, Y | 1 |
| Lai, CF | 1 |
| Wu, KD | 2 |
| Lin, SL | 3 |
| Ng, YY | 2 |
| Tsai, TJ | 3 |
| Lan, XR | 1 |
| Yang, WC | 1 |
| Lan, HY | 2 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Kudaeva, OT | 1 |
| Goiman, EV | 1 |
| Lykov, AP | 1 |
| Kolesnikova, OP | 1 |
| Kozlov, VA | 1 |
| Steinmann-Niggli, K | 2 |
| Ziswiler, R | 1 |
| Küng, M | 1 |
| Marti, HP | 2 |
| Wardle, EN | 1 |
| Daniel, C | 1 |
| Duffield, J | 1 |
| Brunner, T | 1 |
| Lods, N | 1 |
| Rumiantsev, ISh | 1 |
| Kaznacheeva, IG | 1 |
| Abdiadilova, LV | 1 |
| Kozlov, VV | 1 |
| Shoĭkhet, IN | 1 |
| Treĭvish, VS | 1 |
| Novikova, NN | 1 |
1 review available for pentoxifylline and Bright Disease
| Article | Year |
|---|---|
Can pentoxifylline prevent renal disease?
Topics: Diabetic Nephropathies; Glomerulonephritis; Humans; Nephritis, Interstitial; Pentoxifylline; Phospho | 1998 |
10 other studies available for pentoxifylline and Bright Disease
| Article | Year |
|---|---|
Pentoxifylline Attenuates Proteinuria in Anti-Thy1 Glomerulonephritis via Downregulation of Nuclear Factor-κB and Smad2/3 Signaling.
Topics: Anaplastic Lymphoma Kinase; Animals; Cytokines; Disease Models, Animal; Gene Expression; Glomerulone | 2015 |
Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats.
Topics: Animals; Disease Models, Animal; Fibrosis; Glomerulonephritis; Kidney; Male; Models, Biological; Pen | 2009 |
Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats.
Topics: Animals; Disease Models, Animal; DNA Primers; Glomerulonephritis; Macrophages; Male; Pentoxifylline; | 2004 |
Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Topics: Animals; Blood Pressure; Body Weight; Cell Proliferation; Cyclic GMP; Drinking; Fibrosis; Glomerulon | 2006 |
Effects of preparations modifying Th1/Th2 ratio on the incidence of clinical variants of chronic graft-versus-host reaction.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Anti-Glomerular Basement Membrane Disease; Benzhydryl Co | 2005 |
Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Chemokine CCL2; Creatinine; Cytokines; Female; Glomerul | 2006 |
Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis.
Topics: Animals; Benzyl Compounds; Cell Count; Cells, Cultured; Creatinine; Dexamethasone; Drug Combinations | 1998 |
Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells.
Topics: Animals; Annexin A5; Apoptosis; Benzyl Compounds; Cell Cycle; Dexamethasone; Dose-Response Relations | 2001 |
[The effect of pathogenetic therapy on the expression of endogenous intoxication in patients with chronic glomerulonephritis].
Topics: Chronic Disease; Cyclophosphamide; Drug Therapy, Combination; Glomerulonephritis; Heparin; Humans; M | 1992 |
[Pentoxifylline (Trental) in the treatment of chronic glomerulonephritis].
Topics: Adolescent; Adult; Chronic Disease; Drug Evaluation; Female; Glomerulonephritis; Humans; Hypertensio | 1986 |